ArticleBiological procedures online2026
Targeting Hyaluronan Signaling Overcomes Primary Effusion Lymphoma Cells Resistance to Rapamycin.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oncogenic γ-herpesvirus known as the Kaposi's sarcoma-associated herpesvirus (KSHV) is a principal causative agent of several cancers arising in patients with compromised immune systems. One of KSHV-related malignancies, primary effusion lymphoma (PEL), comprises transformed B cells harboring the viral episome and arises preferentially within the pleural or peritoneal cavities of patients including those with HIV infection. PEL is a rapidly progressing malignancy with a median survival time of several months even with conventional chemotherapy. One of the major reasons causing PEL chemotherapy failure is multidrug chemoresistance of lymphoma cells, however, there are only limited data exploring the mechanisms of PEL chemoresistance. In the current study, we demonstrate the role of hyaluronan (HA) signaling activation in rapamycin resistance in PEL cells, and that targeting HA signaling by small HA oligosaccharides (oHA) can augment rapamycin efficacy against PEL expansion in vivo. Our results provide the framework for the development of HA-targeted therapies clinical trials for PEL patients, which may represent promising adjuncts to reduce chemotherapy toxicity, improve treatment and prolong patients' survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.